Seres Therapeutics, Inc.MCRBNASDAQ
LOADING
|||
Switch Symbol:
EPS Growth Accelerating
Trending higher, above historical average.
Left:
||||
Year-over-year earnings per share growth rate
Latest
141.25%
↑ 2249% above average
Average (39q)
6.01%
Historical baseline
Range
High:307.75%
Low:-319.79%
CAGR
+0.9%
Modest growth trend
| Period | Value |
|---|---|
| Q3 2025 | 141.25% |
| Q2 2025 | -160.47% |
| Q1 2025 | 307.75% |
| Q4 2024 | 76.19% |
| Q3 2024 | -74.93% |
| Q2 2024 | 21.02% |
| Q1 2024 | 13.92% |
| Q4 2023 | 14.45% |
| Q3 2023 | -202.33% |
| Q2 2023 | 164.46% |
| Q1 2023 | -2.93% |
| Q4 2022 | -12.19% |
| Q3 2022 | 30.21% |
| Q2 2022 | -14.21% |
| Q1 2022 | -12.91% |
| Q4 2021 | -173.19% |
| Q3 2021 | 241.00% |
| Q2 2021 | -36.08% |
| Q1 2021 | -94.17% |
| Q4 2020 | 44.95% |
| Q3 2020 | -28.29% |
| Q2 2020 | -0.66% |
| Q1 2020 | -4.86% |
| Q4 2019 | -14.11% |
| Q3 2019 | 1.57% |
| Q2 2019 | 59.81% |
| Q1 2019 | -14.06% |
| Q4 2018 | 3.32% |
| Q3 2018 | 20.90% |
| Q2 2018 | 1.45% |
| Q1 2018 | 3.31% |
| Q4 2017 | -319.79% |
| Q3 2017 | 75.36% |
| Q2 2017 | -9.52% |
| Q1 2017 | 0.00% |
| Q4 2016 | 100.00% |
| Q3 2016 | 34.29% |
| Q2 2016 | -40.00% |
| Q1 2016 | 0.00% |
| Q4 2015 | 100.00% |